Profarma (PFRM3) reports gross revenue of R$ 4.5 bn in 3Q26

Adjusted EBITDA rises 31.6% to R$ 150.5 mn; adjusted net income falls 11.2%

Editorial Team Visno InvestPublished 11/13/2026 00:03

PFRM3Profarma DistribuiçãoR$ 7.69as of 11/11/2026Price, ratios and dividends

Illustrative image: Profarma Distribuição

Grupo Profarma (PFRM3) reported consolidated gross revenue of R$ 4.5 bn in the third quarter of 2026 (3Q26), up 35.6% from 3Q25. The exact figure was R$ 4,490.6 mn, driven by growth in all three business units and the consolidation of 4BIO, acquired in May 2026. Without that effect, growth would have been 9.3%.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding IFRS 16 effects and non-recurring items) totaled R$ 150.5 mn, up 31.6%, with a margin of 3.9% of net revenue, versus 4.0% in 3Q25. Net revenue was R$ 3,868.9 mn (+35.7%) and gross profit was R$ 577.2 mn (+29.1%), with a gross margin of 14.9%.

Adjusted net income was R$ 46.7 mn, down 11.2% from R$ 52.6 mn in 3Q25. According to the company, the result reflects R$ 19.5 mn in charges on obligations to the sellers of 4BIO, a R$ 7.4 mn increase in depreciation and amortization, and R$ 4.1 mn more in income tax and social contribution. Over the last 12 months, adjusted net income was R$ 128.5 mn, down 8.4%, and operating cash flow totaled R$ 219.2 mn.

Total net debt ended the quarter at R$ 1.4 bn, consisting of R$ 827.7 mn in net bank debt and R$ 537.2 mn in obligations from the purchase of 4BIO. Leverage (net debt to EBITDA) stood at 2.8x, or 1.8x excluding 4BIO. In October, the company completed the third debenture issuance, approved on October 8, of R$ 300 mn, at CDI + 1.45% per year, with a 5-year term.

By unit, Profarma Distribuição had gross revenue of R$ 3.5 bn (+10.6%) and EBITDA of R$ 92.6 mn (+9.4%). Rede d1000 recorded gross revenue of R$ 728.7 mn (+7.0%) and EBITDA of R$ 30.6 mn, flat. 4BIO had gross revenue of R$ 871.1 mn (+15.3% over pro forma 3Q25) and EBITDA of R$ 26.8 mn (+49.0%), with a margin of 3.5%.

In the document, the company also reported that, on October 26, BTC Participações, an affiliate of BMK Participações, signed a definitive agreement to acquire BPL's 38.18% stake in Profarma and come to hold 66% of the group. Closing depends on CADE approval and other conditions of the agreement.